Pre–clinical validation has often been slow due to a lack of accurate models for the disease and the lack of validation expertise. But the Multiple Myeloma Research Foundation is addressing this challenge with our Validation Team, a network of highly skilled researchers specializing in the science of compound validation.

Our Validation Team is now screening our dynamic "pipeline" of compounds, diligently testing every compound against the best and most predictive validation models and advancing into clinical trials those that show the most potential in treating patients. Because it is unlikely that a single drug will treat a complex cancer like multiple myeloma, we are simultaneously validating combinations of compounds—pairing new therapies like Velcade® and Revlimid® with other promising compounds—to find the best combinations to most effectively treat the disease.

As each new compound is advanced into clinical trials, we stock our pipeline by fostering partnerships with pharmaceutical and biotech companies that focus on myeloma or that have a promising compound that could be redirected to the treatment of myeloma. We work hand in hand to rapidly validate these compounds and shepherd those that show the most promise into rigorously designed clinical trials.